Simulating the contribution of a biospecimen and clinical data repository in a phase II clinical trial: A value of information analysis
暂无分享,去创建一个
Benjamin M Craig | Murat K. Munkin | David Fenstermacher | D. Fenstermacher | Benjamin Matthew Craig | Gang Han | Murat K Munkin | Gang Han
[1] V. Sondak,et al. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Susanne B Haga,et al. Ethical, legal, and social implications of biobanks for genetics research. , 2008, Advances in genetics.
[3] Geoffrey S Ginsburg,et al. Centralized biorepositories for genetic and genomic research. , 2008, JAMA.
[4] J. Ghosh,et al. Approximations and consistency of Bayes factors as model dimension grows , 2003 .
[5] B. Druker,et al. Translation of the Philadelphia chromosome into therapy for CML. , 2008, Blood.
[6] H. Greely. The uneasy ethical and legal underpinnings of large-scale genomic biobanks. , 2007, Annual review of genomics and human genetics.
[7] C. Compton. The Surgical Specimen Is the Personalized Part of Personalized Cancer Medicine , 2009, Annals of Surgical Oncology.
[8] M. Nesline,et al. Establishing a Cancer Center Data Bank and Biorepository for Multidisciplinary Research , 2006, Cancer Epidemiology Biomarkers & Prevention.
[9] J. Pow-Sang,et al. Phase II Trial of B7-1 (CD-86) Transduced, Cultured Autologous Tumor Cell Vaccine Plus Subcutaneous Interleukin-2 for Treatment of Stage IV Renal Cell Carcinoma , 2008, Journal of immunotherapy.
[10] M. Fishman,et al. Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy. , 2007, Urologic oncology.
[11] G. Bepler,et al. Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancer. , 2005, Chest.
[12] G. Mills,et al. Future of personalized medicine in oncology: a systems biology approach. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] G. Bepler,et al. Phase II Study of First-Line Sequential Chemotherapy with Gemcitabine-Carboplatin Followed by Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer , 2005, Oncology.
[14] C. Compton. Getting to personalized cancer medicine , 2007, Cancer.
[15] J. Ross,et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.
[16] Elisa Eiseman,et al. Handbook of human tissue sources : a national resource of human tissue samples , 1999 .
[17] Nicholas R. Anderson,et al. Meeting the Governance Challenges of Next-Generation Biorepository Research , 2010, Science Translational Medicine.
[18] Howard M. Proskin,et al. Taking Out the Garbage , 2006 .
[19] G. Bepler,et al. Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer , 2006, Clinical Cancer Research.
[20] P. Munster,et al. Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response , 2008, Cancer.
[21] Alan Cantor,et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Bryan R Luce,et al. Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational Change , 2009, Annals of Internal Medicine.
[23] C. Obasaju,et al. Clinical Efficacy and Predictive Molecular Markers of Neoadjuvant Gemcitabine and Pemetrexed in Resectable Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[24] C. Moskaluk,et al. Tissues from population-based cancer registries: a novel approach to increasing research potential. , 2005, Human pathology.
[25] Eric B Haura,et al. Phase 2 trial of docetaxel and gefitinib in the first‐line treatment of patients with advanced nonsmall‐cell lung cancer (NSCLC) who are 70 years of age or older , 2008, Cancer.
[26] Helen M. Moore,et al. 2009 Biospecimen research network symposium: advancing cancer research through biospecimen science. , 2009, Cancer research.
[27] S. Tunis,et al. Does comparative-effectiveness research threaten personalized medicine? , 2009, The New England journal of medicine.
[28] S. Bates,et al. Progress towards personalized medicine. , 2010, Drug discovery today.
[29] V. Sondak,et al. Phase II trial of sagopilone (ZK-EPO), a novel synthetic epothilone, with significant activity in metastatic melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.